Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023418 (
leukemia
)
93,477
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In this issue of
Cancer Discovery
, Cai and colleagues delineate a new mechanism that links cell of origin, the transcription factor
EVI1
, apoptotic priming, and therapeutic susceptibility in mixed lineage
leukemia
-rearranged acute myeloid leukemia. These findings establish a cell of origin-dependent program that may be leveraged by therapeutic combinations to overcome drug resistance in chemoresistant leukemias.
See related article by Cai et al., p. 1500
.
...
PMID:Therapy Response and Outcome Explained by Leukemia Cell of Origin. 3260 37
The transcriptional regulator
EVI1
has an essential role in early development and haematopoiesis. However, acute myeloid leukaemia (AML) driven by aberrantly high
EVI1
expression has very poor prognosis. To investigate the effects of post-translational modifications on
EVI1
function, we carried out a mass spectrometry (MS) analysis of
EVI1
in AML and detected dynamic phosphorylation at serine 436 (S436). Wild-type
EVI1
(
EVI1
-WT) with S436 available for phosphorylation, but not non-phosphorylatable
EVI1
-S436A, conferred haematopoietic progenitor cell self-renewal and was associated with significantly higher organised transcriptional patterns. In silico modelling of
EVI1
-S436 phosphorylation showed reduced affinity to CtBP1, and CtBP1 showed reduced interaction with
EVI1
-WT compared with
EVI1
-S436A. The motif harbouring S436 is a target of CDK2 and CDK3 kinases, which interacted with
EVI1
-WT. The methyltransferase DNMT3A bound preferentially to
EVI1
-WT compared with
EVI1
-S436A, and a hypomethylated cell population associated by
EVI1
-WT expression in murine haematopoietic progenitors is not maintained with
EVI1
-S436A. These data point to
EVI1
-S436 phosphorylation directing functional protein interactions for haematopoietic self-renewal. Targeting
EVI1
-S436 phosphorylation may be of therapeutic benefit when treating
EVI1
-driven
leukaemia
.
...
PMID:EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal. 3308 7
<< Previous
1
2
3
4
5
6
7
8
9
10